| Literature DB >> 26199934 |
Seong Ho Lee1, Sang Kon Lee1, Min Soo Choo1, Kyung Tae Ko1, Tae Young Shin1, Won Ki Lee1, Tsolmon Batsaikhan1, ShanAi Quan2, Jin Young Jeong3, Dong Hyun Kim4.
Abstract
The aim of the study was to test the hypothesis that the metabolic syndrome (MS) is linked to lower urinary tract symptoms (LUTS) in Korean men. This was a longitudinal study that used data collected from 328 men aged 50-89 years who were randomly selected among 1,520 participants in 2004. We collected information from 224 (68.3%) men among the original responders on the biological, medical, psychological, social, lifestyle, and economic factors in 2007. The prevalence of the MS was 187/328 (57.0%) in 2004 and 125/224 (55.8%) in 2007 among men, respectively. There was no significantly greater increase in the IPSS in men with the MS than in men without the MS over a 3-year period of time (2.0 ± 9.37 versus 3.0 ± 8.44, p = 0.402, resp.). In the multivariate logistic regression analysis with control for age and life style factors, the risk factors for moderate/severe LUTS were age and erectile dysfunction (p < 0.05). However, the presence of the MS did not increase the risk of moderate/severe LUTS (OR = 1.09, 95% CI 0.63-1.89, p = 0.748). Our cross-sectional and longitudinal risk factor analyses do not support the hypothesis that the MS is linked to LUTS in Korean men.Entities:
Mesh:
Year: 2015 PMID: 26199934 PMCID: PMC4493267 DOI: 10.1155/2015/130917
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
General characteristics for the study population according to severity of LUTS.
| LUTS | Total |
| |||
|---|---|---|---|---|---|
| No/mild | Moderate | Severe | |||
| Number of respondents (%) | 135 (41.2) | 130 (39.6) | 63 (19.2) | 328 (100) | |
| Age (years) | 67.5 ± 8.4 | 70.9 ± 7.1 | 71.8 ± 6.5 | 69.7 ± 7.8 | <0.001a |
| MS (%) | |||||
| (+) | 78 (41.7) | 73 (39) | 36 (19.3) | 187 (100) | 0.958b |
| (−) | 57 (40.4) | 57 (40.4) | 27 (19.2) | 141 (100) | |
| WC (cm) | 89.0 ± 7.6 | 87.2 ± 8.2 | 87.4 ± 9.2 | 88.0 ± 8.2 | 0.222a |
| BMI (kg/m2) | 25.2 ± 2.7 | 24.5 ± 2.7 | 24.3 ± 3.5 | 24.8 ± 2.9 | 0.085a |
| Hypertension (%) | 40 (29.6) | 40 (30.8) | 23 (36.5) | 103 (29.3) | 0.612b |
| DM (%) | 19 (14.1) | 14 (10.8) | 10 (15.9) | 43 (12.3) | 0.561b |
| Hyperlipidemia (%) | 7 (5.2) | 2 (1.5) | 1 (1.6) | 10 (2.8) | 0.170b |
| IIEF-5 | 14.5 ± 8.3 | 10.2 ± 8.9 | 8.0 ± 8.0 | 11.5 ± 8.8 | <0.001a |
| Height (cm) | 162.7 ± 6.9 | 162.9 ± 6.6 | 163.2 ± 6.3 | 162.9 ± 6.6 | 0.898a |
| Weight (kg) | 66.8 ± 9.2 | 65.4 ± 9.3 | 64.9 ± 10.4 | 65.9 ± 9.5 | 0.351a |
| Total cholesterol (mg/dL) | 192.1 ± 35.1 | 185.8 ± 33.6 | 189.3 ± 36.5 | 189.1 ± 34.8 | 0.347a |
| Education (yr) | 7.1 ± 4.6 | 7.0 ± 4.7 | 7.5 ± 4.6 | 7.1 ± 4.6 | 0.823a |
| Income (10,000 won, %) | 0.009b | ||||
| <600 | 38 (28.1) | 67 (51.5) | 31 (49.2) | 136 (41.5) | |
| 600–1800 | 44 (32.6) | 26 (20.0) | 15 (23.8) | 85 (25.9) | |
| 1800–3600 | 22 (16.3) | 15 (11.5) | 9 (14.3) | 46 (14.0) | |
| >3600 | 6 (4.4) | 2 (1.5) | 0 (0) | 8 (2.4) | |
| Smoking (%) | 0.883b | ||||
| None | 29 (21.5) | 24 (18.5) | 10 (15.9) | 63 (19.2) | |
| Ex | 66 (48.9) | 64 (49.2) | 31 (49.2) | 161 (49.1) | |
| Current | 40 (29.6) | 42 (32.3) | 22 (34.9) | 104 (31.7) | |
| Regular exercise (%) | 41 (30.4) | 41 (31.5) | 15 (23.8) | 73 (22.3) | 0.470b |
| Lab | |||||
| Total cholesterol (mg/dL) | 192.1 ± 35.1 | 185.8 ± 33.6 | 189.3 ± 36.5 | 189.1 ± 34.8 | 0.347a |
| Uric acid (mg/dL) | 5.7 ± 1.5 | 5.7 ± 1.4 | 5.5 ± 1.6 | 5.7 ± 1.5 | 0.564a |
| Creatinine (mg/dL) | 1.02 ± 0.23 | 1.01 ± 0.19 | 1.21 ± 1.34 | 1.05 ± 0.62 | 0.080a |
| CRP (mg/L) | 0.27 ± 0.78 | 0.33 ± 0.57 | 0.17 ± 0.17 | 0.27 ± 0.62 | 0.331a |
| MMSE | 26.5 ± 3.1 | 25.9 ± 2.8 | 26.1 ± 2.8 | 26.2 ± 3.0 | 0.480a |
| GDS | 9.8 ± 6.4 | 13.8 ± 6.7 | 15.5 ± 6.5 | 12.4 ± 6.9 | <0.0001a |
LUTS: lower urinary tract symptoms; MS: metabolic syndrome; WC: waist circumference; BMI: body mass index; DM: diabetes mellitus; IIEF-5: 5-item version of the International Index of Erectile Function; CRP: c-reactive protein; MMSE: Mini-Mental State Examination; GDS: geriatric depression scale. aANOVA test. bChi-square test.
Figure 1Prevalence and severity of the metabolic syndrome (a) and lower urinary tract symptoms (LUTS) (b) in different age groups of study population.
Multivariate logistic regression analysis of risk factors associated with LUTS.
| Moderate-to-severe LUTS |
| Moderate-to-severe LUTS |
| |
|---|---|---|---|---|
| MS | ||||
| No | 1 | 1 | ||
| Yes | 1.005 (0.635–1.589) | 0.913 | 1.094 (0.634–1.886) | 0.748 |
| Age | — | 1.066 (1.023–1.111) | 0.003 | |
| IIEF-5 | 0.960 (0.929–0.992) | 0.014 | 0.956 (0.924–0.989) | 0.010 |
| Smoking | 1.002 (0.999–1.004) | 0.150 | 1.001 (0.999–1.004) | 0.264 |
| Alcohol intake | 1.000 (0.998–1.002) | 0.994 | 1.000 (0.998–1.001) | 0.774 |
| No regular exercise | 1.116 (0.649–1.918) | 0.691 | 1.331 (0.717–2.471) | 0.364 |
| Total cholesterol | 0.997 (0.990–1.004) | 0.304 | 0.997 (0.989–1.005) | 0.471 |
Comparisons between included and excluded participants in the 2007 study.
| Included participants ( | Excluded participants ( |
| |
|---|---|---|---|
| Age (years) | 71.4 ± 7.4 | 72.8 ± 8.3 | 0.272 |
| MS (%) | 125 (55.8) | 61 (58.6) | 0.552 |
| WC (cm) | 88.3 ± 7.4 | 87.4 ± 9.4 | 0.387 |
| BMI (kg/m2) | 24.92.7 | 24.6 ± 3.2 | 0.435 |
| Hypertension (%) | 72 (32.1) | 32 (30.7) | 0.646 |
| DM (%) | 28 (12.5) | 15 (14.4) | 0.650 |
| Hyperlipidemia (%) | 9 (4.0) | 2 (1.9) | 0.217 |
| IIEF-5 | 12.1 ± 8.7 | 10.5 ± 9.0 | 0.150 |
| Smoking (%) | 0.867 | ||
| None | 42 (20.9) | 21 (20.1) | |
| Ex | 108 (53.7) | 53 (50.9) | |
| Current | 51 (25.4) | 30 (28.8) | |
| Regular exercise (%) | 67 (33.3) | 30 (23.6) | 0.134 |
| Alcohol (g/day) | 53.2 ± 158.2 | 39.9 ± 100.0 | 0.395 |
| Total cholesterol (mg/dL) | 190.4 ± 35.2 | 187.0 ± 34.1 | 0.403 |
MS: metabolic syndrome; WC: waist circumference; BMI: body mass index; DM: diabetes mellitus; IIEF-5: 5-item version of the International Index of Erectile Function.
The longitudinal changes in the metabolic syndrome and LUTS in a total of 224 subjects.
| Year | LUTS (%) | MS (%) | ||
|---|---|---|---|---|
| No/mild | Moderate | Severe | ||
| 2004 | 100 (44.6) | 84 (37.5) | 40 (17.9) | 125 (55.8) |
| 2007 | 71 (31.7) | 92 (41.1) | 61 (27.2) | 131 (58.5) |
|
| ||||
|
| 0.008 | 0.532 | ||
(a) Storage IPSS
| 2004 | 2007 |
| |
|---|---|---|---|
| MS (−) | 4.22 ± 4.02 | 5.51 ± 3.86 | 0.023 |
| MS (+) | 4.20 ± 3.85 | 5.49 ± 4.01 | 0.010 |
|
| |||
|
| 0.984 | ||
(b) Voiding IPSS
| 2004 | 2007 |
| |
|---|---|---|---|
| MS (−) | 6.93 ± 6.33 | 7.65 ± 6.00 | 0.412 |
| MS (+) | 6.19 ± 6.13 | 7.90 ± 5.62 | 0.022 |
|
| |||
|
| 0.250 | ||
(c) Total IPSS
| 2004 | 2007 |
| |
|---|---|---|---|
| MS (−) | 11.15 ± 9.34 | 13.16 ± 9.33 | 0.133 |
| MS (+) | 10.39 ± 8.54 | 13.4 ± 8.98 | 0.007 |
|
| |||
|
| 0.402 | ||
2004 versus 2007 IPSS in each group (paired t-test).
†2004 versus 2007 IPSS between MS (−) and MS (+) (2-way ANOVA test).